歌礼制药-B二零二四年年报

2456827314963109114115116118119120181 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 24840 198D12 Walkers Corporate Limited190 Elgin AvenueGeorge TownGrand Cayman KY1-9008Cayman Islands 183171712-1716 1526 108 1672 www.ascletis.com (i)ASC30286.3%(ii)ASC30GLP-1R(iii)ASC47β(THRβ)ASC4740 (i)ASC30286.3%(ii)ASC30GLP-1R(iii)ASC47β(THRβ)ASC4740 1,980.82,299.4 216.839.5%302.4 144.7300.9 1.SagimetASC40 GLP-1RGLP-1THRββFASNVEGF ASC30 ASC30(BMI)30-40 kg/m2Ib(MAD)(NCT06680440) ASC3028MAD14.3%MAD26.3%MAD14.2%MAD26.2% MAD12ASC30SAE(GI)AE12ASC30MAD1(ALT)(AST)(TBL)ECGsQT(QTc) ASC30 ASC30GLP-1RASC30(NCE) 13IIa ASC30 ASC30Ib ASC30Ib(SAD)(NCT06679959)BMI30-40kg/m2IbSAD87668ASC30,21214 ASC3040NHPs16ASC30 GLP-1ASC30 Ib ASC47 ASC47IbFDAASC 47(semaglutide)IND ASC47LDL-CIb2640 ASC47900.2%291.0%431.7%50ASC47 ASC4790SAEAEAE1 DIOASC472056.7%LDL-CISAD(NCT06427590)ASC4721ASC4790SAEAEAE1AE ASC47THRβASC47 ASC47 ASC22 RSVASC10 HIVASC22 MASH MASHASC40 MASHASC41 ASC41III (rGBM)ASC40 GBMIV1GBM57%2.854.561046.4GBM2GBM56.6%3.21103 ASC61 I ASC40 6.4430%40%5 III 18A.05 1.Louis N, Perry A, Reifenberge RG, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World HealthOrganization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803-20.2.20173.Ostrom Q T, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary Brain and Other Central NervousSystem Tumors Diagnosed in the United States in 2011-2015 [J]. Neuro Oncol 2018, 20 (suppl_4): iv1-iv86. DOI:10.1093/neuonc/noy131.4.Tan J K, Bhate K. A global perspective on the epidemiology of acne [J]. Br J Dermatol 2015, 172 Suppl 1(3-12).DOI: 10.1111/bjd.13462.5.Purvis CG, Balogh EA, Feldman SR. Clascoterone: How the Novel Androgen Receptor Inhibitor Fits Into the AcneTreatment Paradigm. Ann Pharmacother. 2021;55(10):1297-1299. doi: 10.1177/1060028021992055. 17,000 11 1.ASC30Ib2.13ASC30IIa3.ASC474.5. 1,980.82,299.4 56.61.3 30.60.5 0.726.0 184.735.1%119.8(i)60.621.1SagimetSagimet(ii)24.5SagimetSagimet24.5 0.4HCV 115.612.0%101.7 (i)(ii)(iii) 216.839.5%302.4 0.20.1 2.1453.1%11.8 1. 6.14.4 5.40.2® 3090 14.336.2%9.1 4.169.8%1.2 53.5SagimetSagimet 24.87.4 34.066.0 40.945.7 15.311.2 56.113.7 341.6355.4 978.9866.0 103.598.5 5.262.4%2.0 VikingTherapeutics,Inc.VikingASC41ASC43FITCUSDC ITCITCASC41ASC43F1930337567,0004,038,000VikingITC USDCVikingUSDC 0.60.2 (1)(2)(3) (1)(2)(3)100% 16.612.916.512.8 6.0%7.5% 23122981.3% 136.1144.0 6.46.5 62 •PowerTree••••••AP11 Limited•SoundRidge Pharmaceuticals (Hong Kong) Co., Limited••Gannex, LLC•ASCLETIS (AUSTRALIA) PTY LTD 27SagimetSGMTGSKHIVAmbriliaProcyonAMBPhageTechInc.PhageTech Inc.Immunex CorporationNovartis Pharmaceuticals CorporationNVS (University of Arizona) 51 •••Gannex, LLC•• 50 22 52 600637UTUTStarcomIncUTSI(HK2699)688099大發地產集團有限公司HK6111(HK1817)Vesync Co., LtdHK2148)(HK2440)(HK1318)(HK0953) 51 000608 (University of Greenwich) John P. GARGIULO65John P. Gargiulo3218 Gargiulo 5519 20 14 567826 A •••••• 30 2730 89 826 3.13 HCVHIV HBV 33A3314A14A.76(1)14A.95 XV352 (1)L(2)1,012,758,000(3)JJW12 Limited514,393,664(4)1,155,5001,000,000(5)Lakemont Holding LLC82,827,414Lakemont Holding LLCLakemontRemainderTrust45.95%NorthridgeTrust53.52%Lakemont Remainder TrustNorthridgeTrustLakemont Holding LLC(6)1,155,5001,000,000(7)41,692,000JJW12 LimitedJJW12Limited41,692,000 352 336 (1)L(2)1,012,758,000(3)JJW11 Limited(4)JJW12 Limited514,393,66441,692,000JJW12 Limited41,692,000(5)LakemontHolding LLCLakemontRemainder Trust45.95%NorthridgeTrust53.52%Lakemont Holding LLC(6)C-Bridge Capital GP, Ltd.64,154,727C-Bridge Capital GP, Ltd.TF Capital II, Ltd.TF Capital,Ltd.38.34%45.00%Fu WeiTF Capital II, Ltd.47.83%(7)Yang DanKang Hua Investment Company Limited105,463,060 336 100.0%99.4%53.0%55.4% 35.7%32.3%11.6%11.1% 5% 11411929 29 29 2,935.62,994.6 449,000 11 224,137,0000.000114.003,137,918,0002,730,284,000 (i)(ii)(iii)(iv) 30.8%82.2%(i)63.6%(ii) 18.6%ASC47IbLDL-CASC30BMI30-40kg/m2IbMADASC30GLP-1R30.8%ASC47ASC30 78,004,000107,834,120 41,692,000 1. 2. (a)(b)(c)(d)(e)(f) 3. 4. 10% (a)10%(b)(c) (a) (b)17.03C(3) 30% 5. 121% (a) (b)17.03D(2) (c) 6. 7. (a) (b) (c) 6,300,000 7. 7. (a) (b)4,563,0001,710,000 (%)0.00(%)73.00(%)3.362.20 – 2.801.30(%)0.00 92,055,34598,355,345 6,300,0000.65% 0.0063 4962 4,820,1755,784,210 C1 2C.2.1 2730 2C.5.1 2C.2.1 C12C.2.1(i)(ii)(iii) 3.13 2 3.10(2)3.21 2A.2.1 2371217.03(F)(i)(ii) 2E.1.5 1,000,0011,500,0002,500,0013,000,0004,500,0015,000,000 51.95%48.05% (i)(ii)(iii) 109113 64 221 24840ir@ascletis.com www.ascletis.com ESGESG C2 KPIs ESG ( www.hkex.com.hk )(www.ascletis.com) 24840ir@ascletis.com GMP ESG •••••• ESG ESGESGESGESGESG ESGESGESGESG •••• •••••••• ••••• ••• ••••••••• •••• 1 25ESG ESG 12345678910 ESG 111213141516171819202122 ESG 232425 ASC30ASC30AS